Introduction
Thrombopoietin (TPO) is a newly cloned hematopoietic growth factor and functions as a primary regulator of megakaryocytopoiesis and thrombopoiesis. [1] [2] [3] [4] [5] [6] The receptor for TPO, c-Mpl, is encoded by the proto-oncogene c-mpl which was originally identified as the cellular homologue of the protooncogene v-mpl transduced into myeloproliferative leukemia virus, and has high sequence similarity to the receptors for erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF), thereby belonging to a member of the hematopoietic growth factor receptor superfamily. In normal hematopoietic tissues, expression of c-mpl is detected primarily in CD34 + hematopoietic cells, megakaryocytic progenitor cells, megakaryocytes, and platelets, and thus TPO was first thought to be a lineage-restricted hematopoietic growth factor. [7] [8] [9] [10] Several lines of the in vitro and in vivo evidence, however, revealed that TPO plays an important physiological roles in regulating early hematopoiesis by itself [11] [12] [13] or in synergy with other hematopoietic growth factors. [14] [15] [16] [17] [18] [19] A number of studies have suggested that dysregulated expression of hematopoietic growth factors and/or their receptors could be involved in excessive proliferation and aberrant differentiation of leukemia cells. [20] [21] [22] [23] [24] It has been shown that c-mpl is detected by Northern blot (NB) analysis in a half of the patient samples of acute myeloblastic leukemia (AML) and myelodysplastic syndrome (MDS), and the TPO/c-Mpl interaction is implicated in the proliferation or megakaryocytic differentiation of the myeloblasts in some cases. [21] [22] [23] [24] [25] However, only a little is known about c-mpl expression and its role in leukemia cells of lymphoid lineage.
In the present study, to evaluate a functional role of the TPO/c-Mpl system in lymphoid leukemia cells, we tested a total of 23 human lymphoid leukemic cell lines for the c-Mpl expression by Western blot (WB) and flow cytometry (FC) in addition to the c-mpl expression by reverse transcriptase-polymerase chain reaction (RT-PCR), and then examined the effect of TPO on their 3 H-thymidine incorporation, colony formation, and induction of tyrosine phosphorylation. Several primary samples from acute lymphoblastic leukemia (ALL) patients were also evaluated on these issues.
Materials and methods

Hematopoietic growth factors and antibodies
Recombinant human (rh) TPO, GM-CSF, and IL-3, and rabbit anti-human c-Mpl (extracellular domain) IgG were kindly provided by Kirin Brewery (Takasaki, Gunma, Japan). Anti-phosphotyrosine monoclonal (4G10) and rabbit anti-JAK2 polyclonal antibodies were obtained from UBI (Lake Placid, NY, USA), while rabbit anti-Shc antibody was from Transduction Laboratory (Lexington, KY, USA).
Leukemia cells
Twenty-three human lymphoid leukemic cell lines (T-lineage 4, B-lineage 19) were used in this study. The B-lineage cell lines consisted of six with 11q23 translocation, six with Philadelphia chromosome (Ph1), five with other karyotypic abnormalities, and two derived from leukemic stage of Burkitt's lymphoma (BK). Their phenotypic and cytogenetic characteristics are listed in Table 1 , and have been described previously. [26] [27] [28] Fresh leukemia cells were separated from peripheral blood or bone marrow of nine patients with B-precursor ALL (Ph1 5, 11q23 translocation 1, other 3) by density-gradient centrifugation. These cells contained Ͼ95% blasts on cytospin smears. 
RT-PCR analysis
Total cellular RNA was prepared using the acid guanidine isocyanate method. 10 g of total RNA was reverse-transcribed with the following method. RNA was boiled at 80°C for 3 min with 9 l of anneal buffer and 250 ng of random primer (Promega, Madison, WI, USA) followed by incubation at 43°C for 60 min with 15 l of cDNA buffer, 5 U of reverse transcriptase (Takara, Tokyo, Japan), and 15 U of RNAsin (Takara). The cDNA product (5 l) was resuspended in a final volume of 25 l containing 0.5 U of Taq DNA polymerase (Takara), 200 mol/l dNTP mix, 10 pmol of primers, and 1× reaction buffer. Primers for c-mpl were as follows: sense 5′-TGGA GATGCAGTGGCACTTG-3′ (position 845 to 864); anti-sense 5′-AGAACTGTGGGGTCTGTAGT-3′ (position 1050 to 1031). The cycling conditions for PCR were 94°C for 1 min for denaturation, 55°C for 1 min for annealing, and 72°C for 1 min for extension, and repeated 35 times. Aliquots (5 l) were resolved on 2.0% agarose gels containing ethidium bromide to examine the size of PCR products. The expected size of PCR product was 207 bp for c-mpl.
WB analysis
The procedure of analysis has been described previously.
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Briefly, 2 × 10 6 leukemic cells were solubilized in lysis buffer Leukemia (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 0.05% NaN 3 , 0.2 TIU/ml aprotinin, 1 g/ml pepstatin A, 10 mM iodoacetamide, 1 mM phenylmethylsulfonyl fluoride, 100 M sodium vanadate). The lysates were separated on a 6% SDS-polyacrylamide gel under reducing conditions and then transferred to a nitrocellulose membrane. The membrane was incubated with anti-c-Mpl antibody at 4°C overnight, and then with horseradish peroxidase-labeled antirabbit antibody at room temperature for 1 h. The bands were developed using an enhanced chemiluminescence detection (ECL) kit (Amersham Japan, Tokyo, Japan).
Analysis of tyrosine phosphorylation of JAK2 and Shc
The cells (1 × 10 7 /well) were treated with TPO (10 ng/ml) in serum-free D-MEM/F12 medium and harvested at several time points. The JAK2 or Shc molecule was then immunoprecipitated using anti-JAK2 or anti-Shc antibody and protein Asepharose beads. The precipitate was eluted by SDS sample buffer, run on a 7.5% SDS-polyacrylamide gel, and transferred to a nitrocellulose membrane. The membrane was incubated with anti-phosphotyrosine antibody (1 g/ml) overnight at room temperature followed by incubation with horseradish peroxidase-labeled anti-mouse antibody at room temperature for 1 h, and then developed as described in WB analysis.
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FC analysis
To detect surface expression of c-Mpl, biotinylated TPO was first produced as reported previously. 28 In brief, 0.5 ml of TPO solution (200 g/ml) dialyzed against sodium bicarbonate (0.2 M, pH 8.4) was mixed with 25 l of biotinyl N-hydroxysuccinimide ester (Sigma, St Louis, MO, USA) in dimethyl sulfoxide (10 mg/ml), and incubated at room temperature for 4 h and at 4°C overnight. The TPO solution was dialyzed against PBS twice to remove unbound biotin. For analysis, 1 × 10 6 leukemic cells were incubated with 2 l of biotinylated TPO. As negative control, 100-fold excess of unlabeled TPO was also added. After incubation for 1 h at 4°C, the cells were washed twice with ice-cold PBS in the presence of 0.05% NaN 3 , and incubated with streptavidin-phycoerythrin (Biomeda, Foster City, CA, USA) for 30 min at 4°C. These cells were washed and analyzed using a flow cytometry (FACScaliber, Becton Dickinson, San Jose, CA, USA). The channel of log fluorescence intensity was determined in each of the samples above which 5% of cells for negative control were included, and the populations appearing above this channel were considered as positive for the TPO receptor.
Changes in morphology and expression of surface antigens after TPO treatment
Leukemic cell lines were cultured in RPMI-1640 supplemented with 10% FCS in the presence or absence of TPO (10 ng/ml). Cultures were started in flat-bottomed six-well plates (4 × 10 6 cells/8 ml). The morphology of the cells was observed every 3 days (up to day 12) on cytospin smears after Wright-Giemsa staining. Surface antigens (CD19, CD13, CD14, CD33, CD41, CD42a) expression was also examined every 3 days (up to day 12) by direct immunofluorescence using a flow cytometer.
H-thymidine uptake assay
5 × 10 5 leukemia cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) in triplicate in a 96-well culture plate (Costar, Cambridge, MA, USA) at 37°C for 72 h in the presence or absence of cytokines (TPO 10 ng/ml, IL-3 10 ng/ml, GM-CSF 10 ng/ml, IL-3 + TPO, or GM-CSF + TPO). In some experiments, cells were cultured with various concentrations (0, 1, 10, 100 ng/ml) of TPO. Subsequently, wells were pulsed with 3 H-thymidine (Amersham) (1 Ci/well) for 4 h after which the cells were harvested. 
Colony formation assay
Leukemia cells (5 × 10 4 /dish) were suspended in a semi-solid ␣-MEM medium containing 1% methyl cellulose, 20% FCS, 1% bovine serum albumin, and 10 −5 M 2-mercaptoethanol, and incubated in duplicate in 35-mm dishes at 37°C in 5% CO 2 for 14 days with or without cytokines (TPO 10 ng/ml, IL-3 10 ng/ml, GM-CSF 10 ng/ml, IL-3 + TPO or GM-CSF + TPO). The number of clusters (Ͻ50 cells) and colonies (Ͼ50 cells) was counted on light microscopy. In some experiments, cells were removed from cultures with a micropipette, affixed on to slides using a cytocentrifuge, and observed by a light microscope after Wright-Giemsa staining.
Results
Expression of c-mpl mRNA and c-Mpl protein
We examined the expression of c-mpl/c-Mpl in a total of 23 human lymphoid leukemic cell lines by three distinct methods: RT-PCR, WB, and FC. The results were summarized in Table 1 .
By RT-PCR, the c-mpl mRNA of 207 bp was demonstrated in 20 cell lines, but not in three cell lines (T-lymphoid 1, BK 2) as depicted in Figure 1 , suggesting that c-mpl is expressed in human lymphoid leukemic cell lines at a higher frequency than reported previously. 25 We next examined the c-Mpl expression in c-mpl mRNA-positive cell lines by WB, and found that all of the B-lineage, but not T-lineage, cell lines expressed this receptor. Doublet forms of the c-Mpl protein were detected in 13 cell lines, while the single form in five cell lines as depicted in Figure 2 and summarized in Table 1 . The c-Mpl expression was not revealed in three c-mpl mRNAnegative cell lines (lanes 1, 6 and 8 in Figure 2 
Effect of TPO on 3 H-thymidine uptake
Using representative lymphoid leukemic cell lines (T-lineage 3, B-lineage 12), we examined the effect of TPO on their proliferation by the 3 H-thymidine uptake assay in the presence or absence of other cytokine (IL-3 or GM-CSF). As shown in Table 2 , proliferation of two cell lines (KOCL-33 and KOPN55bi) expressing c-Mpl at highest levels, was enhanced by an addition of TPO (10 ng/ml) resulting in more than 70% stimulation, although no synergistic effect with IL-3 or GM-CSF was demonstrated. We next examined proliferative responses to various concentrations of TPO in these two cell lines. KOPN55bi with Ph1 responded to TPO in a dose-dependent manner, showing the maximal % stimulation at 100 ng/ml of TPO, while response to TPO in KOCL-33 with 11q23 translocation reached the maximal level at a concentration of 1 ng/ml (Figure 4) . A B-lineage cell line KOPN-62 showed proliferative response to IL-3 or GM-CSF, but not to TPO (Table 2) . No proliferative response to cytokines was observed in the other 12 cell lines examined.
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Figure 3
Surface expression of c-Mpl on FC analysis. (a) Leukemic cell lines; (b) primary leukemia cells. The broken and solid lines showed cytofluorographics stained with biotinylated TPO in the presence or absence of 100-fold excess of unlabeled TPO, respectively. The horizontal and vertical axes represent log fluorescence intensity and cell number, respectively.
Effect of TPO on colony formation
Using 15 representative cell lines used in the 3 H-thymidine uptake assay, the long-term effect of TPO on proliferation was addressed by the colony formation assay. While no effects were observed in 13 cell lines, the colony-forming activity of KOCL-33 and KOPN-55bi was promoted by the addition of TPO ( Table 2 ). As shown in Figure 5a , KOCL-33 cells formed a large number of clusters and few colonies in the culture condition without cytokines, but an addition of TPO as well as IL-3 or GM-CSF increased the number of colonies, resulting in the cluster/colony ratio of 14. In addition, TPO modestly promoted the colony-forming activity in synergy with IL-3 (cluster/colony ratio: 7.5). Of note, most of the clusters were markedly up-regulated in size by a combined addition of TPO and GM-CSF, resulting in appearance of large colonies consisting of thousands of cells as depicted in Figure 5b . Similar results were observed in KOPN-55bi (data not shown). 
Effect of TPO on morphology and surface antigens expression
No morphological changes of KOCL-33 and KOPN-55bi were observed after suspension culture containing TPO with or without other cytokines. Changes in expression of several surface antigens were also not demonstrated.
Induction of tyrosine phosphorylation by TPO
It is known that TPO triggers tyrosine phosphorylation of several molecules including JAK2 and STAT5 in platelets, megakaryocytes, c-Mpl transfectants, and myeloid cells, which play crucial roles in the process of the c-Mpl-mediated signal transduction. [29] [30] [31] [32] The adapter protein Shc is also known to be involved in this process. 30, 31 To verify whether TPO induces tyrosine phosphorylation in B-precursor cell lines, KOCL-33 cells were stimulated by TPO (20 ng/ml) and changes in tyrosine phosphorylation of JAK2 (130 kDa) and Shc (52/46 kDa) were pursued by anti-phosphotyrosine mAb on WB. As shown in Figure 6 , tyrosine phosphorylation of both molecules were markedly upregulated within 1 min after TPO stimulation. This result indicates that machinery of signal transduction pathways after the TPO/cMpl interaction is functionally prepared in KOCL-33.
Analysis of primary leukemia cells
To address whether or not the TPO/c-Mpl interaction revealed in the leukemic cell lines are also observed in primary leukemia cells, we performed similar experiments using leukemia cells freshly separated from patients with B-precursor ALL (Ph1 5, 11q23 translocation 1, other 3). As summarized in Table 3 , the blasts from patients 1-5 with Ph1 and patient 6 with 11q23 translocation expressed c-Mpl on FC (12-91%), whereas those from patients 7-9 with other karyotype did not show any expression at all. Representative positive (patient 1) and negative (patient 7) cytofluorographics were shown in Figure 3b . Further, in the 3 H-thymidine uptake analysis of seven patients, a significantly stimulated responses of the blasts to TPO were observed in patients 1-4 and 6, but not in patients 8 and 9. Patients 1 and 6 showed a maximal response at a concentration of 1 ng/ml of TPO (% stimulation:
Figure 5
The effect of cytokines on colony formation of KOCL-33. (a) Number of clusters (light column) and colonies (dark column) 14 days after culture with or without cytokines (TPO, IL-3, IL-3 + TPO, GM-CSF, GM-CSF + TPO). (b) Size of colonies under light microscopic observation 14 days after culture with or without cytokines (TPO, GM-CSF, GM-CSF + TPO).
Figure 6
Changes in tyrosine phosphorylation of JAK2 and Shc. KOCL-33 cells were stimulated with TPO and harvested at indicated time points. Status of the JAK2 and Shc tyrosine phosphorylation was examined as described in Materials and methods.
101 and 68%), while patients 2-4 at a concentration of 10 ng/ml of TPO (% stimulation: 76, 174, and 85%).
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Discussion
In the present study, we showed that the B-precursor leukemia cells, particularly those with 11q23 translocation or Ph1, expressed surface c-Mpl, and the TPO/c-Mpl interaction was involved in their proliferation which was more frequently observed in primary leukemia cells than in established cell lines. It is noteworthy that the functional c-Mpl expression is observed in not only myeloid but also lymphoid leukemia cells with specific chromosomal abnormalities.
The c-mpl mRNA was demonstrated by RT-PCR in 20 of 23 human lymphoid cell lines (three of four T-lineage, 17 of 19 B-lineage), suggesting that a large population of lymphoid leukemic cell lines express c-mpl at least at a transcriptional level. Graf G et al 25 reported that c-mpl mRNA was detectable by RT-PCR only in two of six B-lineage cell lines and one of three T-lineage cell lines. Although a reason why their and our results showed discrepancy regarding the detection rate of c-mpl mRNA in lymphoid leukemic cell lines by RT-PCR is unclear at present, one possible explanation is that the cmpl mRNA expression might be considerably restricted to lymphoid leukemia cells with specific chromosomal abnormalities which were extensively examined in our study. Alternatively, different sensitivities in detecting c-mpl mRNA by RT-PCR analysis may be responsible. Although sense and antisense primers are identically set, our conditions are less stringent and thus expected to have, to some extent, higher sensitivity than theirs (annealing temperature: 55 vs 58°C, annealing time: 60 vs 30 s, and 35 vs 32 PCR cycles). Of note, the c-Mpl protein expression was not detectable by WB in Tlineage cell lines with c-mpl mRNA, suggesting that their cmpl mRNA is at very low levels and thereby has not been detected by NB as reported previously by Drexler HG et al. 25, 33 In addition, surface expression of c-Mpl was revealed by FC at a variety of densities in 13 of 20 c-mpl mRNA + cell lines. Thus, flow cytometric analysis proved a useful methodology for a quantitative demonstration of the surface c-Mpl expression. Of interest, the moderate to high surface expression (Ͼ40%) of c-Mpl was almost restricted in eight of 12 cell lines with 11q23 translocation or Ph1. Primary leukemia cells with Ph1 or 11q23 translocation also frequently and considerably expressed the surface c-Mpl. Takeshita et al 34 reported that the blasts from two of 14 ALL cases expressed the surface c-Mpl, but their karyotypic findings were not presented. Thus, this is the first identification of the linkage between the surface c-Mpl expression on lymphoid leukemia cells and specific chromosomal abnormalities. Since leukemia cells with 11q23 translocation or Ph1 is thought to arise from cells at a stage close to hematopoietic stem cells, 26 higher expression of c-Mpl on these leukemia cells may reflect the nature of normal counterparts from which they originated. We have recently shown leukemia cells with 11q23 translocation or Ph1 express G-CSF receptor. 28, 35 In this regard, these Bprecursor leukemia cells may express receptors for a variety of cytokines which have been believed to be expressed primarily on non-lymphoid leukemia cells.
We have previously shown that proliferation of leukemia cells with 11q23 translocation or Ph1 is frequently stimulated with G-CSF. 28, 35 We demonstrated in this study that both primary leukemia cells and established cell lines with 11q23 translocation or Ph1 were considerably responsive to TPO in the 3 H-thymidine uptake assay, the former was more sensitive than the latter. In the experiments using leukemic cell lines with 11q23 translocation or Ph1 whose proliferation was stimulated in the 3 H-thymidine uptake assay, only a weak stimulative effect was observed by addition of TPO alone in the colony formation assay, but a combined addition of GM-CSF and TPO markedly increased the size of colonies. Moreover, triggering of c-Mpl by TPO induced tyrosine phosphorylation of JAK2 and Shc in these cell lines. Thus, TPO may play a physiological role in the growth regulation of B-precursor leukemia cells particularly with 11q23 translocation or Ph1, although their TPO receptor expression does not always imply that they respond to TPO. In preclinical studies in normal mice and non-human primates, administration of TPO resulted in a rapid rise in platelet counts. 36, 37 In myelosuppressed animal models, use of TPO following chemotherapy, radiation, or hematopoietic stem cell transplantation accelerated recovery of megakaryocytopoiesis and thrombopoiesis. Although the peripheral effect is selective on platelet-megakaryocyte lineage, TPO mediates stimulatory effects on progenitors of multiple cell lineages at the bone marrow level and mobilizes progenitor cells into the peripheral blood. 38 Thus, TPO has rapidly moved from the laboratory to the clinic in the last 3 years. Preliminary results of clinical trials using the truncated or full-length form of the molecule indicate that TPO is useful in the treatment of chemotherapy-induced thrombocytopenia. 39 However, clinical use of TPO after chemotherapy might not be recommended in ALL with 11q23 translocation or Ph1 because there is the possibility that TPO may facilitate relapse of the disease. To conclude, long-term observation and multicentric analysis will be required because use of TPO may improve event-free survival by shortening the interval between programs of chemotherapy like a role of G-CSF in the treatment of AML. 40 On the contrary, it is highly possible that use of TPO during chemotherapy enhances the cytotoxic effects of anti-leukemic agents by inducing these leukemic cells from G 0 -phase into the chemotherapy-sensitive G 1 -and S-phases as reported in GM-CSF. 41 In this regard, it may be very useful to use both TPO and G-CSF, together with a preconditioning regimen, in autologous or allogeneic hematopoietic stem cell transplantation for leukemia with 11q23 translocation or Ph1.
